Higher-Dose, Two-Session Vaginal Brachytherapy Proves Effective for Endometrial Cancer Treatment
• A randomized clinical trial led by Huntsman Cancer Institute demonstrates that two sessions of high-dose vaginal brachytherapy are as effective as standard multiple low-dose treatments for endometrial cancer.
• The SAVE trial findings offer a more convenient treatment option for patients, particularly benefiting those in rural areas who face challenges accessing multiple treatment sessions.
• Research shows comparable short-term outcomes and minimal acute toxicities between the new two-session approach and traditional 3-5 session treatment protocol.
Nivolumab Plus AVD Emerges as New Standard for Advanced Hodgkin Lymphoma Treatment
• Phase 3 SWOG S1826 trial demonstrates superior efficacy of nivolumab combined with AVD compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma.
• The nivolumab-AVD combination showed better tolerability with no new safety signals, establishing itself as a new standard of care for advanced-stage Hodgkin lymphoma patients.
• Clinical findings indicate improved treatment outcomes with N+AVD, marking a significant advancement in the therapeutic landscape for stage III and IV Hodgkin lymphoma.
Real-World Data Confirms High Effectiveness of RSV Vaccines in Older Adults
• A real-world study found RSV vaccines offer approximately 80% protection against severe illness and hospitalization for adults aged 60 and older.
• The study included data from multiple U.S. healthcare networks, representing 230 hospitals and 245 emergency departments nationwide.
• The analysis showed the vaccine's benefit was particularly evident in adults aged 75 and older, the most vulnerable age group.
• Findings highlight the potential for significant cost savings due to reduced RSV-related hospitalizations, estimated between $1.2 and $5 billion annually.
Hydroxychloroquine Fails to Prevent or Treat COVID-19 in Multiple Trials
• A University of Minnesota study found that hydroxychloroquine did not prevent COVID-19 infection in high-risk healthcare workers, with 5.9% of the hydroxychloroquine group and 7.9% of the placebo group developing the virus.
• The NIH's ORCHID trial concluded that hydroxychloroquine provides no clinical benefit to hospitalized adults with COVID-19, with similar health status observed in both hydroxychloroquine and placebo groups after 14 days.
• Both studies reported side effects, such as nausea and upset stomach, but no increased risk of serious cardiac complications from hydroxychloroquine compared to placebo.
• These findings align with other trials, reinforcing that hydroxychloroquine is not an effective treatment for preventing or improving outcomes in COVID-19 patients.
© Copyright 2025. All Rights Reserved by MedPath